Corresponding Author: Markus Schmitt, German Cancer Research Center (DKFZ), INF 242, Heidelberg 69120, Germany.
Cancer Epidemiol Biomarkers Prev. 2013 Mar;22(3):406-14. doi: 10.1158/1055-9965.EPI-12-1067. Epub 2013 Jan 18.
Infections with high-risk human papillomaviruses (Hr-HPV) can cause malignant transformation of the human cervical epithelium. HPV DNA tests generally are very sensitive to detect cervical neoplastic lesions but also identify transient HPV infections. As a consequence, the specificity and positive predictive value are low.
We analyzed viral load of Hr- and possibly Hr-HPV types more than seven orders of magnitude (on a log10 scale) in 999 consecutive BD-SurePath liquid-based cervical cytology samples from routine cervical screening enriched with atypical squamous cells of undetermined significance (n = 100), low-grade squamous intraepithelial lesions (LSIL; n = 100), and high-grade squamous intraepithelial lesions (HSIL; n = 97) using type-specific multiplex quantitative real-time PCR and the BSGP5+/6+-PCR/MPG assay. In the 36-month follow-up, 79 histologically verified CIN2+ and 797 double-negative cytology cases were identified.
Viral loads in LSIL and HSIL were significantly increased compared with no intraepithelial lesion or malignancy in both the quantitative PCR (qPCR) and BSGP5+/6+-PCR/MPG assay (P < 0.0001). The mean viral loads in LSIL and HSIL were not significantly different. Using a newly determined high viral load cut off for 14 Hr-HPV types, the sensitivity for prevalent CIN3+ remained at 100% for both assays compared with the minimal detection threshold. The specificity (corresponding to double-negative cytology at subsequent screening episodes) increased substantially (qPCR, from 91.1% to 95.7%; BSGP5+/6+-PCR/MPG, from 79.8% to 96.2%).
Compared with DNA positivity alone, high Hr-HPV viral loads could reduce the amount of false positive results detected by the BSGP5+/6+-PCR/MPG and qPCR by 81.4% and 52.1%, respectively.
Quantitative type-specific HPV DNA assays show high flexibility in defining thresholds that allow optimizing clinical accuracy for cervical cancer precursors.
高危型人乳头瘤病毒(Hr-HPV)感染可导致人宫颈上皮恶性转化。HPV DNA 检测通常对检测宫颈肿瘤性病变非常敏感,但也会识别一过性 HPV 感染。因此,其特异性和阳性预测值较低。
我们分析了 999 例连续的 BD-SurePath 液基细胞学样本中的 Hr-HPV 及可能的 Hr-HPV 类型的病毒载量,这些样本来自常规的宫颈筛查,其中包括非典型鳞状细胞意义不明确(ASC-US;n=100)、低级别鳞状上皮内病变(LSIL;n=100)和高级别鳞状上皮内病变(HSIL;n=97),采用了型特异性多重实时定量 PCR 和 BSGP5+/6+-PCR/MPG 检测。在 36 个月的随访中,共发现 79 例经组织学证实的 CIN2+和 797 例细胞学双阴性病例。
LSIL 和 HSIL 中的病毒载量与无上皮内病变或恶性肿瘤相比,在定量 PCR(qPCR)和 BSGP5+/6+-PCR/MPG 检测中均显著升高(P<0.0001)。LSIL 和 HSIL 中的平均病毒载量无显著差异。使用新确定的 14 种 HR-HPV 类型的高病毒载量截断值,与最小检测阈值相比,两种检测方法对现患 CIN3+的敏感性均保持在 100%。特异性(对应于后续筛查中细胞学双阴性)显著增加(qPCR 从 91.1%增加至 95.7%;BSGP5+/6+-PCR/MPG 从 79.8%增加至 96.2%)。
与 DNA 阳性相比,高 HR-HPV 病毒载量可分别将 BSGP5+/6+-PCR/MPG 和 qPCR 检测到的假阳性结果数量减少 81.4%和 52.1%。
定量型特异性 HPV DNA 检测具有高度的灵活性,可定义阈值,优化宫颈癌前病变的临床准确性。